Authors
Lina Maria Rayo Abella, Joachim Neumann, Britt Hofmann, Uwe Kirchhefer, Ulrich Gergs
Published in
Naunyn-Schmiedeberg's archives of pharmacology. Sep 29, 2025. Epub Sep 29, 2025.
Abstract
Felcisetrag (methyl 4-[[4-[[(2-propan-2-yl-1H-benzimidazole-4-carbonyl)-amino]-methyl]-piperidin-1-yl]methyl]piperidine-1-carboxylate, TD-8954, TAK-954) has a structural formula with similarity to serotonin. It is one of the most potent compounds to bind to recombinant human 5-HT4-serotonin receptors. We noted that felcisetrag raised force of contraction in left atrial preparations (LA) and beating rate in right atrial preparations (RA) from mice with cardiac-specific overexpression of the human 5-HT4 receptors (5-HT4-TG) but was inactive in LA and RA from adult wild type mouse hearts (WT). When felcisetrag had increased force of contraction in LA or beating rate in RA of 5-HT4-TG, GR125487, a 5-HT4 receptor antagonist, reduced force of contraction and beating rate. Felcisetrag raised force of contraction only in the presence of cilostamide in human right atrial preparations (HAP) obtained from adult patients during open heart surgery due to severe coronary heart disease. These positive inotropic effects of felcisetrag in HAP were attenuated by 1 µM GR125487. In the presence of cilostamide, 100 nM felcisetrag exerted positive inotropic effects that were increased further by 1 µM serotonin. When 1 µM serotonin had raised force of contraction, additionally applied 100 nM felcisetrag reduced force of contraction in HAP. These data suggest that felcisetrag can act as an agonist as well as an antagonist at human 5-HT4 receptors in the mammalian heart.
PMID:
41020940
Bibliographic data and abstract were imported from PubMed on 29 Sep 2025.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 43
- Comments 0